Sold as Gallium Citrate Ga 67, Neoscan. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 4 applications for Gallium Citrate Ga-67 (sold as Gallium Citrate Ga 67, Neoscan), first approved May 17, 1976, with 2 new uses approved and 0 published complete response letters.
| May 17, 1976 | Gallium Citrate Ga 67NDA 17478 · New molecular entity | Lantheus Medcl | 11 | Discontinued |
| Dec 16, 1977 | Gallium Citrate Ga 67NDA 17700 · New formulation or manufacturer | Ge Healthcare | 3 | Discontinued |
| May 1, 1978 | NeoscanNDA 17655 · New formulation or manufacturer | Ge Healthcare | 7 | Discontinued |
| Feb 1, 1979 | Gallium Citrate Ga 67NDA 18058 · New formulation or manufacturer | Curium | 9 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Ge Healthcare